|
10 Oct 2019 |
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
|
|
10 Oct 2019 |
MGB Biopharma Announces Promising Phase IIa Clinical Trial Update for MGB-BP-3, a Novel, Potent Bactericidal Antibiotic Targeting Clostridium difficile-Associated Diarrhoea (CDAD)
|
|
10 Oct 2019 |
EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain
|
|
10 Oct 2019 |
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases
|
|
10 Oct 2019 |
Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer
|
|
10 Oct 2019 |
Bayer and RIKEN Innovation establish partnership in drug discovery
|
|
10 Oct 2019 |
Oncologie Announces First Patient Enrolled in Global Phase 2 Study of Bavituximab Plus KEYTRUDA® (Pembrolizumab) for Advanced Gastric or Gastroesophageal Cancer
|
|
10 Oct 2019 |
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
|
|
10 Oct 2019 |
Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
|
|
10 Oct 2019 |
Avacta Group plc Enters Collaboration and Option Agreement With ADC Therapeutics
|
|
10 Oct 2019 |
Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate-to-Severe Atopic Dermatitis
|
|
10 Oct 2019 |
UCB agrees to acquire Ra Pharmaceuticals: Joining forces to improve treatment options for people living with myasthenia gravis and other rare diseases
|
|
09 Oct 2019 |
bluebird bio and Novo Nordisk Enter into Research Agreement to Develop in vivo Genome Editing Candidates for Haemophilia and Other Severe Genetic Diseases
|
|
09 Oct 2019 |
Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
|
|
09 Oct 2019 |
Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma
|
|
09 Oct 2019 |
City of Hope Is Enrolling Patients in First of Its Kind Clinical Trial for Brain Tumor Patients
|
|
09 Oct 2019 |
Novartis data show more patients are completely symptom-free from chronic spontaneous urticaria with ligelizumab (QGE031) than Xolair® 300 mg
|
|
08 Oct 2019 |
FDA approves first treatment to increase pain-free light exposure in patients with a rare disorder
|
|
08 Oct 2019 |
Azitra Presents Data Showing Tolerability of its Lead Product Candidate ATR-04
|
|
08 Oct 2019 |
AVROBIO Announces First Patient Dosed in Phase 1/2 Trial of Gene Therapy for Cystinosis
|
